Amyris (NASDAQ:AMRS) Issues Quarterly Earnings Results

Amyris (NASDAQ:AMRSGet Rating) announced its earnings results on Tuesday. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07), Briefing.com reports. The business had revenue of $57.71 million for the quarter, compared to the consensus estimate of $65.45 million. During the same quarter in the prior year, the business posted ($1.08) earnings per share. The firm’s revenue for the quarter was down 67.4% on a year-over-year basis.

Shares of Amyris stock traded up $0.03 on Wednesday, hitting $1.76. 958,137 shares of the company traded hands, compared to its average volume of 5,507,079. The company has a 50-day moving average price of $4.15 and a 200 day moving average price of $5.64. The company has a quick ratio of 2.09, a current ratio of 2.37 and a debt-to-equity ratio of 1.26. Amyris has a 12-month low of $1.71 and a 12-month high of $17.42. The company has a market cap of $559.64 million, a PE ratio of -0.90 and a beta of 1.63.

AMRS has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Amyris from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 3rd. StockNews.com initiated coverage on shares of Amyris in a research note on Thursday, March 31st. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $19.17.

Institutional investors have recently bought and sold shares of the company. Vident Investment Advisory LLC grew its holdings in shares of Amyris by 6.7% during the 4th quarter. Vident Investment Advisory LLC now owns 372,081 shares of the biotechnology company’s stock valued at $2,013,000 after acquiring an additional 23,228 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Amyris by 5.3% during the 4th quarter. California State Teachers Retirement System now owns 235,363 shares of the biotechnology company’s stock valued at $1,273,000 after acquiring an additional 11,858 shares in the last quarter. Legal & General Group Plc boosted its holdings in Amyris by 1.7% in the fourth quarter. Legal & General Group Plc now owns 137,498 shares of the biotechnology company’s stock worth $744,000 after purchasing an additional 2,305 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in Amyris by 145.6% in the third quarter. BNP Paribas Arbitrage SA now owns 45,735 shares of the biotechnology company’s stock worth $628,000 after purchasing an additional 27,110 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Amyris in the fourth quarter worth $487,000. Institutional investors and hedge funds own 49.43% of the company’s stock.

About Amyris (Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Recommended Stories

Earnings History for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.